The France Mammography Market size is estimated at USD 109.67 million in 2024, and is expected to reach USD 167.5 million by 2029, growing at a CAGR of 8.84% during the forecast period (2024-2029).
The healthcare sector of France was adversely affected, as the demand decreased during the first wave of COVID-19 to keep hospitals and clinics free for COVID-19 patients and the risk of spreading the infection. Thus, all non-essential treatments and surgeries were postponed by healthcare institutions. Due to the panic created by the authorities across all social platforms, women were more than anxious about COVID-19 infection while getting their mammograms, which impacted the follow-up tests. In the initial months of the COVID-19 pandemic i.e. in April 2020, the diagnostic centers, magnetic resonance imaging laboratories, and X-ray clinics were forced to temporarily shut down to reorganize by the French government's new public health norms and guidelines. Although they eventually restarted, social distancing norms limited the number of patients at a particular time. However, during the year 2021, as the pandemic situation was in control, the elective breast cancer screenings started and the market was able to carry its momentum shortly. As per the article published by the National Institute of Health in October 2021 titled, 'Impact of the COVID-19 lockdown in France on the diagnosis and staging of breast cancers in a tertiary cancer center,' the COVID-19 lockout was associated with a 20% decline in breast cancer diagnoses. Breast tumors discovered after the lockdown had a worse outcome due to delayed diagnosis, larger tumor masses, and increased rates of nodal invasion. Hence, it is observed that the COVID pandemic had a significant impact on the market studied in France.
Being a developed country, France is witnessing higher adoption of the digital mamography systems. The growing research articles proving the efficacy of the technology is growing in the country creating the awareness of these systems and encouraging many facilities to adopt these advanced and accurate systems. For instance, Paolo Giorgi Rossi, in the article, 'Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk', published specifically for France in 2021, stated that breast density assessed with new fully automated method is positively associated with BC risk and is not inferior to radiologists' visual assessment. The study concludes that digital systems are efficient and no where any less than the physician assessment and eliminates the doubt form many patients who believe direct assessment is more efficient.
Hence, with the increasing significance of mammograms across the country, the market studied is expected to witness healthy growth over the forecast period.
Serena Pacilè, in the article' Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool', published in 2020, evaluated the benefits of artificial intelligence (AI)-based tools for two-dimensional mammography in the breast cancer detection process. The study concluded that the AI tool improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.
Additionally, Akram M. Asbeutah, in the article 'Comparison of radiation doses between diagnostic full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT): a clinical study, published in 2020, stated that all the non-parametric statistical tests showed a significant difference between entrance surface dose and average glandular dose for full-field digital mammography and digital breast tomosynthesis techniques. The Average Glandular Dose (AGD) for a single-view DBT was lower than the two-view FFDM technique, proving that DBT is more efficient than the FFDM, boosting its demand in the country.
This product will be delivered within 2 business days.
The healthcare sector of France was adversely affected, as the demand decreased during the first wave of COVID-19 to keep hospitals and clinics free for COVID-19 patients and the risk of spreading the infection. Thus, all non-essential treatments and surgeries were postponed by healthcare institutions. Due to the panic created by the authorities across all social platforms, women were more than anxious about COVID-19 infection while getting their mammograms, which impacted the follow-up tests. In the initial months of the COVID-19 pandemic i.e. in April 2020, the diagnostic centers, magnetic resonance imaging laboratories, and X-ray clinics were forced to temporarily shut down to reorganize by the French government's new public health norms and guidelines. Although they eventually restarted, social distancing norms limited the number of patients at a particular time. However, during the year 2021, as the pandemic situation was in control, the elective breast cancer screenings started and the market was able to carry its momentum shortly. As per the article published by the National Institute of Health in October 2021 titled, 'Impact of the COVID-19 lockdown in France on the diagnosis and staging of breast cancers in a tertiary cancer center,' the COVID-19 lockout was associated with a 20% decline in breast cancer diagnoses. Breast tumors discovered after the lockdown had a worse outcome due to delayed diagnosis, larger tumor masses, and increased rates of nodal invasion. Hence, it is observed that the COVID pandemic had a significant impact on the market studied in France.
Being a developed country, France is witnessing higher adoption of the digital mamography systems. The growing research articles proving the efficacy of the technology is growing in the country creating the awareness of these systems and encouraging many facilities to adopt these advanced and accurate systems. For instance, Paolo Giorgi Rossi, in the article, 'Validation of a new fully automated software for 2D digital mammographic breast density evaluation in predicting breast cancer risk', published specifically for France in 2021, stated that breast density assessed with new fully automated method is positively associated with BC risk and is not inferior to radiologists' visual assessment. The study concludes that digital systems are efficient and no where any less than the physician assessment and eliminates the doubt form many patients who believe direct assessment is more efficient.
Hence, with the increasing significance of mammograms across the country, the market studied is expected to witness healthy growth over the forecast period.
France Mammography Market Trends
Breast Tomosynthesis is Expected to Witness Healthy Growth Over the Forecast Period
Breast tomosynthesis, also known as digital breast tomosynthesis (DBT)/3D mammography, is a new technology that helps in improving the radiologist's ability to diagnose breast cancer. These types of mammography use a series of two-dimensional images to build a three-dimensional image of the breast.Serena Pacilè, in the article' Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool', published in 2020, evaluated the benefits of artificial intelligence (AI)-based tools for two-dimensional mammography in the breast cancer detection process. The study concluded that the AI tool improved the diagnostic performance of radiologists in the detection of breast cancer without prolonging their workflow.
Additionally, Akram M. Asbeutah, in the article 'Comparison of radiation doses between diagnostic full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT): a clinical study, published in 2020, stated that all the non-parametric statistical tests showed a significant difference between entrance surface dose and average glandular dose for full-field digital mammography and digital breast tomosynthesis techniques. The Average Glandular Dose (AGD) for a single-view DBT was lower than the two-view FFDM technique, proving that DBT is more efficient than the FFDM, boosting its demand in the country.
France Mammography Industry Overview
The France mammography market is a consolidated one, owing to the presence of a few major players in the market. The major market players are focusing on technological advancements and reducing the side effects of the procedures. Some of the major players in the market are Analogic Corporation, Canon Medical Systems Corporation, Fujifilm Corporation, GE Healthcare, Hologic Inc., Koninklijke Philips NV, and Siemens Healthineers.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Methodology
LOADING...
